Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. - Wikidata - wikimedia - TriplyDB

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

http://www.wikidata.org/entity/Q35844057

about

Smallpox vaccines for biodefense: need and feasibility The evolution of poxvirus vaccines Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review Orthopox Viruses: Infections in Humans Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans.GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.Selection of recombinant MVA by rescue of the essential D4R gene.Serological responses in humans to the smallpox vaccine LC16m8.Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.Therapeutic and prophylactic drugs to treat orthopoxvirus infections Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.Smallpox vaccines for biodefense.The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.

P2860

Q22305942-F26B62C5-3930-4E58-A65B-3BAFB86512A3 Q26995905-58B07AB1-EF78-4F9E-8392-29095EE9CDD0 Q27325586-5F2B8FA1-334D-404F-908D-AF9794CD4D1A Q28384852-241945B1-28AB-4005-BB64-62D473A57507 Q28485174-1DF0D67E-436D-477D-B588-B02DE0F6C3F2 Q28742218-CA1CD1AC-86C5-4149-B010-08F40D055750 Q30228332-45EB5340-C479-4EF0-9E1B-FF35D2E6231D Q30375979-B2A0C0B4-DF16-4C05-A1FF-E0FA15B04EF9 Q33328336-E8C7887B-4D31-4950-B5A3-A0FBBB0A172E Q33440600-0D19E01E-D68F-4447-8A2F-B4E5EA7731FE Q33754697-2363104F-DF31-438D-A0A6-EE3B5AD4C33C Q33770909-30FB5B8A-2DBD-402A-AB92-AA5BFD0FD98D Q33815680-20DA75CF-E5E3-48B2-A142-FFBD15601ED6 Q34023265-59D5153A-0D2E-44FD-A308-F5907DBE13FE Q34136736-D0E96A4B-AD5C-4227-BEF2-08C88A7947F4 Q34470311-04499DF1-32F3-491E-8552-B5776F0A2404 Q34502997-EA609CF1-18AA-4564-A404-4BF8F0CE260C Q34556632-78C440F7-6F1E-4A82-B7FC-EB04DF0B84D7 Q34762818-A26F2AA5-89AC-4AB6-AF7F-21D33BE22BDA Q34910424-C3EC55C3-ABEF-405F-AFB7-5666C52AFF7D Q35140284-3E4E7EAE-4D95-469D-96C2-3E2BEF3DAB5E Q35571248-10B825A7-12D1-4489-8637-65C95913E605 Q35667240-32D0801B-BBD8-4262-B3D5-E271BBFD9231 Q35800430-FAEAF40C-7D58-49F2-BD13-D41D7B627546 Q35945094-E9E4A3E5-1E6D-492A-9A35-E690101B1FE7 Q36229406-42A51E3C-474D-4850-B23A-9B3A1A69C12A Q36397581-B4F1D526-10DC-4C25-8D61-0F6686408824 Q36424513-33F34A0C-4B87-414D-A4EF-5CFF610D0A62 Q36456190-5D897CE6-F3AB-42E5-BCB0-4F28708B0810 Q36593175-73342095-6183-4A2D-B164-66D9BB148647 Q36808703-99C23D40-360A-40BD-9091-9AA5A488241D Q36845650-4F661479-9E30-4665-8AC0-681C480F5962 Q36846282-5D216388-07B3-44AB-BA2F-BE0367E7683A Q37009973-A2B09B62-9346-49F2-A396-C0F78F868B51 Q37066691-63EC5212-F9AC-4BF0-BFDB-E9EF7FEBC967 Q37067250-4F2302AF-48EF-4231-80A2-66B2A829D3AF Q37174356-0E95A69D-6DDA-454A-9918-AD2E7FEB40FC Q37269295-0E411096-EC70-4085-80E6-199868E933B6 Q37393765-7061F1CA-F150-4553-B600-E4705CBA3756 Q37524022-0DA8CF9C-B111-4CE1-920E-71EC501EDCDF

P2860

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

http://www.wikidata.org/entity/Q35844057

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@ast

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@en

type

label

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@ast

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@en

prefLabel

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@ast

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@en

P1433

Q35844057-01DE6D76-4547-4715-B1C2-34FC3C04A238

P1476

Q35844057-D5D67B2E-67CE-44F5-8CFE-46303A41892B

P2093

Q35844057-007A0194-D226-431A-A93F-67440F0551E6

Q35844057-027E078D-B108-44B4-BAB3-98745011079D

Q35844057-30F36DDF-427C-419C-81A8-7D465D2DB1CB

Q35844057-40149E8C-FF8D-4B9B-9021-D2844DBB0E04

Q35844057-4A855371-72D9-4248-8EA9-FC07027C2A39

Q35844057-6294DC15-9C32-411F-B4FA-169C7F64E828

Q35844057-8FAD9B16-7936-4773-8913-05E1B1E045F5

Q35844057-9A96B129-8FE9-444D-B33A-BC0FF59BD7A5

Q35844057-9DC95D5E-5CBA-465E-8A80-B969852F64D4

Q35844057-9F172774-7F9A-4C9F-8630-BC14815CF104

P2860

Q35844057-2A7268D6-86EB-4BF0-A64F-263DD930E3B1

Q35844057-2C6941FB-3AC4-4903-86E1-052F7CF2B439

Q35844057-40B3124C-969E-4DD1-8B57-C0F3F3DC5D50

Q35844057-43C1F3BD-F8E0-41D9-8CF0-CBC1DE887A72

Q35844057-4E2A5A60-7CD8-43A8-A095-2CAF0BFBC2AC

Q35844057-54B23076-6C64-40A3-8E9D-54DC9D69B13D

Q35844057-5593BB61-353F-4CCB-BA3E-EA13592958DA

Q35844057-58279B31-F254-40A9-9094-04D25AA6B47E

Q35844057-5BC14BCF-0E97-4329-A4CE-95A9390DA599

Q35844057-65EB972B-8807-4AF8-96F0-4E2365D260BC

P304

Q35844057-12B3713F-E392-4F56-AD57-3ED2E1F4B09C

P31

Q35844057-6A56B20F-5DED-41E9-B12D-B2ED6971B8D5

P356

Q35844057-8DB45E74-0698-4247-A337-1ABD1EF7C8C9

P407

Q35844057-AE0D50C6-16B5-4EF9-AF06-4927F6CB4F1E

P433

Q35844057-0B7F837D-A7F4-443B-969B-EBE4F7BB1A00

P478

Q35844057-005ED580-4CFF-4A93-B524-09AF7B851437

P50

Q35844057-45E026F9-80A8-4F6F-BB9E-382D99E84621

P577

Q35844057-EBC4435A-9425-4C61-BBD8-4C47B6D0A337

P5875

Q35844057-9A1607C4-B704-4D8E-BCD8-9EF3BFAE76DA

P698

Q35844057-7037E9E3-2CC6-4653-8F9D-6E544125B09C

P932

Q35844057-23A2F149-6CBB-4F3B-BF7B-00F0C5D9FB8C

P356

J.VACCINE.2006.10.047

P1433

P1476

Safety, immunogenicity and eff ...... d vaccinia-immune individuals.

@en

P2093

Brenda D Larkin

http://www.w3.org/2001/XMLSchema#string

Ingelise J Gordon

http://www.w3.org/2001/XMLSchema#string

Janie Parrino

http://www.w3.org/2001/XMLSchema#string

Lewis H McCurdy

http://www.w3.org/2001/XMLSchema#string

Lihan Yan

http://www.w3.org/2001/XMLSchema#string

Lin Gu

http://www.w3.org/2001/XMLSchema#string

Mario Roederer

http://www.w3.org/2001/XMLSchema#string

Mary E Enama

http://www.w3.org/2001/XMLSchema#string

Richard A Koup

http://www.w3.org/2001/XMLSchema#string

Robert T Bailer

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox as a Biological Weapon

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Threats in bioterrorism. I: CDC category A agents.

Evaluation of 21st-century risks of smallpox vaccination and policy options.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.

[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]

P304

1513-1525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2006.10.047

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Barney S. Graham

P577

2006-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6671209

http://www.w3.org/2001/XMLSchema#string

P698

17126963

http://www.w3.org/2001/XMLSchema#string

P932

1892755

http://www.w3.org/2001/XMLSchema#string